Researchers now have a better understanding of Alzheimer's disease, but effective treatments for the neurological disorder remain a long way off. A segment yesterday on KQED's Forum examined the challenges involved in testing new therapies and promising advancements in Alzheimer's research.
During the program, Stanford neurologist Geoffrey Kerchner, MD, PhD, commented on a trial to determine whether a new Alzheimer's drug can prevent the onset of the disease in people who are genetically predisposed. He also spoke about other ideas being tested in academics and industry that may yield new therapies for patients already diagnosed with Alzheimer's.
Previously: Stanford neuroscientist discusses the coming dementia epidemic, Alzheimer's disease: Why research is so critical and The long good-bye: Stanford expert discusses Alzheimer's in new podcast